Joel Lewis Galectin Therapeutics Inc (GALT) insider trading activity

Joel Lewis is President and CEO of GALECTIN THERAPEUTICS INC. Currently has a direct ownership of 897,716 shares of GALT, which is worth approximately $781,012. The most recent transaction as insider was on Jan 14, 2022, when has been sold 8,251 shares (Common Stock) at a price of $2.02 per share, resulting in proceeds of $16,667. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 898K

0% 3M change

12.9% 12M change

Total Value Held $781,012

JOEL LEWIS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 14 2022	BUY Grant, award, or other acquisition	$16,667 $2.02 p/Share	8,251 Added 2.61%	307,868 Common Stock
Dec 31 2021	BUY Grant, award, or other acquisition	$16,668 $2.07 p/Share	8,052 Added 2.62%	299,617 Common Stock
Dec 15 2021	BUY Grant, award, or other acquisition	$16,666 $2.25 p/Share	7,407 Added 2.48%	291,565 Common Stock
Nov 30 2021	BUY Grant, award, or other acquisition	$16,666 $2.63 p/Share	6,337 Added 2.18%	284,158 Common Stock
Nov 15 2021	BUY Grant, award, or other acquisition	$16,668 $2.86 p/Share	5,828 Added 2.05%	277,821 Common Stock
Oct 29 2021	BUY Grant, award, or other acquisition	$16,668 $3.17 p/Share	5,258 Added 1.9%	271,993 Common Stock
Oct 15 2021	BUY Grant, award, or other acquisition	$16,668 $3.37 p/Share	4,946 Added 1.82%	266,735 Common Stock
Sep 30 2021	BUY Grant, award, or other acquisition	$16,668 $3.88 p/Share	4,296 Added 1.61%	261,789 Common Stock
Sep 15 2021	BUY Grant, award, or other acquisition	$16,666 $3.73 p/Share	4,468 Added 1.71%	257,493 Common Stock
Aug 31 2021	BUY Grant, award, or other acquisition	$16,667 $3.93 p/Share	4,241 Added 1.65%	253,025 Common Stock
Aug 13 2021	BUY Grant, award, or other acquisition	$16,667 $3.38 p/Share	4,931 Added 1.94%	248,784 Common Stock
Jul 30 2021	BUY Grant, award, or other acquisition	$16,668 $2.75 p/Share	6,061 Added 2.43%	243,853 Common Stock
Jul 15 2021	BUY Grant, award, or other acquisition	$16,667 $2.59 p/Share	6,435 Added 2.63%	237,792 Common Stock
Jun 30 2021	BUY Grant, award, or other acquisition	$16,666 $3.2 p/Share	5,208 Added 2.2%	231,357 Common Stock
Jun 15 2021	BUY Grant, award, or other acquisition	$16,667 $3.5 p/Share	4,762 Added 2.06%	226,149 Common Stock
Jun 01 2021	BUY Grant, award, or other acquisition	$16,666 $3.97 p/Share	4,198 Added 1.86%	221,387 Common Stock
May 14 2021	BUY Grant, award, or other acquisition	$16,666 $4.23 p/Share	3,940 Added 1.78%	217,189 Common Stock
Apr 30 2021	BUY Grant, award, or other acquisition	$16,668 $4.42 p/Share	3,771 Added 1.74%	213,249 Common Stock
Apr 15 2021	BUY Grant, award, or other acquisition	$16,667 $2.23 p/Share	7,474 Added 3.45%	209,478 Common Stock
Mar 31 2021	BUY Grant, award, or other acquisition	$16,666 $2.17 p/Share	7,680 Added 3.66%	202,004 Common Stock
Mar 15 2021	BUY Grant, award, or other acquisition	$16,668 $2.5 p/Share	6,667 Added 3.32%	194,324 Common Stock
Mar 05 2021	BUY Grant, award, or other acquisition	$60,000 $2.22 p/Share	27,027 Added 11.18%	214,684 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	$16,666 $2.24 p/Share	7,440 Added 3.81%	187,657 Common Stock
Feb 15 2021	BUY Grant, award, or other acquisition	$16,666 $2.49 p/Share	6,693 Added 3.58%	180,217 Common Stock
Jan 29 2021	BUY Grant, award, or other acquisition	$16,666 $1.96 p/Share	8,503 Added 4.67%	173,524 Common Stock

Joel Lewis

President and CEO

Norcross, GA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GALT shares.

Notify only if

Value

Insider Trading

Get notified when an Galectin Therapeutics Inc insider buys or sells GALT shares.

Notify only if

Operation

Value

Type

News

Receive news related to GALECTIN THERAPEUTICS INC

Track Activities on GALT

Account